Sanofi SA has identified thienopyrrolotriazine compounds reported to be useful for the treatment of multiple system atrophy, frontotemporal dementia, multiple sclerosis, amyotrophic lateral sclerosis, brain injury, Alzheimer’s and Parkinson’s disease.

Amgen Inc. has patented new quinazoline compounds acting as GTPase KRAS (G12D mutant) inhibitors and thus reported to be useful for the treatment of cancer.

Geode Therapeutics Inc. and Xtalpi Inc. have jointly developed stimulator of interferon genes protein (STING; TMEM173) modulators reported to be useful for the treatment of cancer, infections and autoimmune disease.

Research at MUSC Foundation for Research Development has led to the identification of small molecules targeting the voltage-dependent anion channel (VDAC) NADH binding pocket.

Nanomedsyn has described lysosome targeting chimeras (LYTACs) comprising cation-independent mannose-6-phosphate receptor (IGF-2R)-targeting glycosides covalently linked to TNF-α degradation inducers.

University of Debrecen researchers have prepared dehydroepiandrosterone (DHEA) derivatives reported to be useful for the treatment of atherosclerosis.

Recent Bristol Myers Squibb Co. patents describe new Toll-like receptor 9 (TLR9) antagonists reported to be useful for the treatment of inflammation, autoimmune disease, cancer, fibrosis, nonalcoholic steatohepatitis, chronic kidney disease, primary sclerosing cholangitis and idiopathic pulmonary fibrosis, among others.

Pivalent Therapeutics Inc. has reported the development of phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors.

ATP-dependent RNA helicase A (DHX9) inhibitors have been reported in an Accent Therapeutics Inc. patent as potentially useful for the treatment of cancer.

A Duke Street Bio Ltd. patent details new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.